(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
复制标题
DOI：
10.1186/s13550-015-0082-6
复制
发表时间：
2015
期刊：
影响因子：
3.2
通讯作者：
Tamura K
中科院分区：
文献类型：
--
作者：
Kurihara H;Hamada A;Yoshida M;Shimma S;Hashimoto J;Yonemori K;Tani H;Miyakita Y;Kanayama Y;Wada Y;Kodaira M;Yunokawa M;Yamamoto H;Shimizu C;Takahashi K;Watanabe Y;Fujiwara Y;Tamura K
本研究的目的是确定64Cu-1，4，7，10-tetraazacyclododecane-1，4，7，10-tetraacetic酸-曲妥珠单抗正电子发射断层扫描能否无创地检测HER2阳性乳腺癌的脑转移。对5例HER2阳性乳腺癌脑转移患者在注射约130MBq的64CuDOTA曲妥珠单抗后24或48小时行PET检查。根据5例患者的PET图像，对脑转移瘤的放射性进行了评估。对1例手术病例进行放射自显影、免疫组织化学(IHC)和液质联用(LC-MS/MS)分析，以确定64CuDOTA-曲妥珠单抗的HER2特异性。5例脑转移灶均可在~(64)Cu-DOTA-曲妥珠单抗PET上显示，提示曲妥珠单抗穿过血脑屏障。1例患者经放射自显影、免疫组织化学和LC-MS/MS证实了64Cu-DOTA-曲妥珠单抗具有HER2特异性，铜-DOTA-曲妥珠单抗PET可作为HER2阳性乳腺癌脑转移灶的一种无创性检测方法。UMIN000004170
The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with 64Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab. PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe 64Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of 64Cu-DOTA-trastuzumab. Metastatic brain lesions could be visualized by 64Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of 64Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS. Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer. UMIN000004170
登录
查看更多内容
影响因子：
3.3
作者：
Ono, Makiko;Ando, Masashi;Fujiwara, Yasuhiro
通讯作者：
Fujiwara, Yasuhiro
影响因子：
11.2
作者：
Robinson, MK;Doss, M;Adams, GP
通讯作者：
Adams, GP
影响因子：
5.3
作者：
Lampson LA
通讯作者：
Lampson LA
使用 (64)Cu-DOTA-曲妥珠单抗 PET 对人表皮生长因子受体 2 阳性转移性乳腺癌进行功能成像。
DOI：
10.2967/jnumed.113.122630
发表时间：
2014-01
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Mortimer JE;Bading JR;Colcher DM;Conti PS;Frankel PH;Carroll MI;Tong S;Poku E;Miles JK;Shively JE;Raubitschek AA
通讯作者：
Raubitschek AA
影响因子：
6.2
作者：
Yonemori, Kan;Tsuta, Koji;Fujiwara, Yasuhiro
通讯作者：
Fujiwara, Yasuhiro